Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low – Time to Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week low during trading on Thursday . The stock traded as low as $784.32 and last traded at $784.95, with a volume of 612102 shares traded. The stock had previously closed at $804.33.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent research reports. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Citigroup initiated coverage on Regeneron Pharmaceuticals in a report on Thursday. They set a “neutral” rating and a $895.00 price objective on the stock. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

The business has a fifty day moving average of $985.21 and a 200 day moving average of $1,032.97. The firm has a market cap of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.48% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the business. Sachetta LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Finally, Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.